GlassScriptPhysician profile
Kane M Deem
NPI 1629058805
$720.76
in general payments reported to CMS, 2019-2025
15 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $104.52 | 2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $90.00 | 2025 | Iclusig, Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $82.71 | 2025 | Imfinzi, Enhertu |
| Array Biopharma INC | $69.97 | 2025 | Braftovi, Mektovi, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $54.44 | 2025 | Opdivo, Opdualag |
| Emd Serono, INC. | $53.46 | 2025 | |
| Incyte Corporation | $44.22 | 2025 | Monjuvi, Zynyz, Jakafi |
| Ipsen Biopharmaceuticals, INC | $44.08 | 2025 | Onivyde |
| Janssen Biotech, INC. | $37.85 | 2025 | Talvey, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $26.22 | 2025 | |
| Kyowa Kirin, INC. | $25.99 | 2025 | |
| Glaxosmithkline, LLC. | $25.72 | 2025 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $24.36 | 2025 | Romvimza |
| Astellas Pharma US INC | $18.85 | 2025 | Padcev |
| Eisai INC. | $18.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kane Deem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.